William H. Andrews (biologist)

Last updated

William H. Andrews
Born (1951-12-10) December 10, 1951 (age 72)
Saginaw, Michigan, U.S.
Alma mater University of Georgia
Awards IPO National Inventor of the Year (second place)
Scientific career
FieldsMolecular biology
Institutions Sierra Sciences

William Henry Andrews (born December 10, 1951) is an American molecular biologist and gerontologist whose career is centered on searching for a cure for human aging. Andrews is the founder and president of the biotechnology company Sierra Sciences. [1] In the 1990s, he led the team at Geron Corporation that was the first to successfully identify the genes for human enzyme telomerase. [2] [3] [4] [5] This enzyme is responsible for preventing telomeres from shortening in human primordial germ cells (reproductive cells). [6]

Contents

Early life and education

Andrews was born on December 10, 1951, to television producer Ralph Andrews and Margaret Andrews. As a child, Andrews was told by his father that he should grow up to become a doctor and find a cure for aging. [1] Andrews graduated from Cate School in 1971. He graduated from the University of California, San Diego in 1976 with two BSc degrees in Biology and Psychology, and earned his Ph.D. in Molecular and Population Genetics at the University of Georgia in 1981. [7] [8]

Career

Andrews has been a medical researcher in biotech since 1981. [9] He first worked at the biotechnology company Armos Corporation then Codon Corporation. Codonwas purchased by Schering AG and became Berlex Biosciences. In 1993, Andrews convinced Berlex to send him to an anti-aging conference at Lake Tahoe, California, where he met Calvin Harley of Geron Corporation. [1] Harley gave a speech on the subject of telomeres and telomerase, their discovery in the organism Tetrahymena by Elizabeth Blackburn and Carol Greider, and on the possible connection between telomeres and aging. Harley mentioned that no one had yet been successful in discovering the genes for telomerase in human beings. After the speech, Andrews approached Harley and told him that he could discover the genes for human telomerase for Geron in three months. Harley hired Andrews as Geron's Director of Molecular Biology. Three months and a half months later, Andrews' team cloned the RNA component of telomerase ("hTR"). [1] For this discovery, and the demonstration that the anti-sense of hTR could kill every cancer cell tested, Andrews and 3 members of his team were awarded second place for "National Inventor of the Year" in 1997 by the Intellectual Property Owners Association (first place having been awarded for the invention of the HIV Protease Inhibitor). [10] Andrews' team later co-discovered the protein component of human telomerase ("hTERT") as well. [1] [5]

In 1998, Andrews founded Yonder Technologies, that later became Sierra Sciences in 1999 in Reno, Nevada, with the specific goal of curing human aging. Andrews assembled a team to search for a small molecule(s) that would bind to the telomerase repressor(s), causing the body to constitutively express telomerase in the presence of that molecule(s). [2] From 1999 to 2005, Sierra Sciences' focus was to identify the telomerase repressor protein, in the hopes that a drug could be specifically designed to bind to it. During this time frame, Geron Corporation discovered TA-65, a small-molecule telomerase activator derived from Astragalus membranaceus. Sierra Sciences tested its efficacy, [11] and shortly thereafter, Andrews became the first paying customer to take the supplement. [2]

In 2005, Andrews switched to the "brute force" strategy of developing assays to screen large numbers of random chemicals to determine whether they induced expression of telomerase. [1] In November 2007, after nearly two years of screening, Sierra Sciences discovered the chemical C0056784, [2] which induces approximately 5% as much telomerase as is found in the immortal cancer cell line HeLa. [12] In 2008, using C0057684 as a positive control, Sierra Sciences developed a more sensitive real-time PCR based high-throughput screening assay, the "hTERT RT-PCR assay," with which they were able to screen 4,000 chemicals per week. [12] In 2010, Andrews and Sierra Sciences entered into an agreement with John Anderson, founder of Isagenix International, to use the new assay to screen natural ingredients for telomerase activity. A year later, based on the assay's results, Isagenix launched Product B, a telomase inducing nutraceutical. [13]

Andrews' team developed an hTERT Gene Therapy, using the Adeno-Associated Virus (AAV) as a vector, for research studies. [14] This gene therapy was later licensed to Libella Gene Therapeutics in 2017 to be used in clinical studies. [15]

Andrews is a named inventor on over 50 US-issued patents on telomerase and author of numerous scientific research studies published in peer-reviewed scientific journals. [16]

Personal life

Andrews is an ultramarathon runner. [2] In 2008 [17] and 2009, [18] he successfully completed the Badwater Ultramarathon, a 135-mile race through Death Valley in temperatures approaching 130 °F (54 °C).

Bibliography

Related Research Articles

<span class="mw-page-title-main">Telomere</span> Region of repetitive nucleotide sequences on chromosomes

A telomere is a region of repetitive nucleotide sequences associated with specialized proteins at the ends of linear chromosomes. Telomeres are a widespread genetic feature most commonly found in eukaryotes. In most, if not all species possessing them, they protect the terminal regions of chromosomal DNA from progressive degradation and ensure the integrity of linear chromosomes by preventing DNA repair systems from mistaking the very ends of the DNA strand for a double-strand break.

<span class="mw-page-title-main">Telomerase</span> Telomere-restoring protein active in the most rapidly dividing cells

Telomerase, also called terminal transferase, is a ribonucleoprotein that adds a species-dependent telomere repeat sequence to the 3' end of telomeres. A telomere is a region of repetitive sequences at each end of the chromosomes of most eukaryotes. Telomeres protect the end of the chromosome from DNA damage or from fusion with neighbouring chromosomes. The fruit fly Drosophila melanogaster lacks telomerase, but instead uses retrotransposons to maintain telomeres.

<span class="mw-page-title-main">Thomas Cech</span> American biochemist

Thomas Robert Cech is an American chemist who shared the 1989 Nobel Prize in Chemistry with Sidney Altman, for their discovery of the catalytic properties of RNA. Cech discovered that RNA could itself cut strands of RNA, suggesting that life might have started as RNA. He found that RNA can not only transmit instructions, but also that it can speed up the necessary reactions.

<span class="mw-page-title-main">Hayflick limit</span> Limit to divisions of a normal human cell

The Hayflick limit, or Hayflick phenomenon, is the number of times a normal somatic, differentiated human cell population will divide before cell division stops. However, this limit does not apply to stem cells.

<span class="mw-page-title-main">Geron Corporation</span> American biotechnology company

Geron Corporation is a biotechnology company located in Foster City, California which specializes in developing and commercializing therapeutic products for cancer that inhibit telomerase.

<span class="mw-page-title-main">Michael D. West</span> American biogerontologist

Michael D. West is an American biogerontologist, and a pioneer in stem cells, cellular aging and telomerase. He is the founder and CEO of AgeX Therapeutics, a startup focused on the field of experimental gerontology.

<span class="mw-page-title-main">Dyskeratosis congenita</span> Medical condition

Dyskeratosis congenita (DKC), also known as Zinsser-Engman-Cole syndrome, is a rare progressive congenital disorder with a highly variable phenotype. The entity was classically defined by the triad of abnormal skin pigmentation, nail dystrophy, and leukoplakia of the oral mucosa, and MDS/AML, but these components do not always occur. DKC is characterized by short telomeres. Some of the manifestations resemble premature ageing and cognitive impairment can be a feature. The disease initially mainly affects the skin, but a major consequence is progressive bone marrow failure which occurs in over 80%, causing early mortality.

<span class="mw-page-title-main">Carol W. Greider</span> American molecular biologist and Nobel laureate

Carolyn Widney Greider is an American molecular biologist and Nobel laureate. She joined the University of California, Santa Cruz as a Distinguished Professor in the department of molecular, cell, and developmental biology in October 2020.

<span class="mw-page-title-main">Telomerase reverse transcriptase</span> Catalytic subunit of the enzyme telomerase

Telomerase reverse transcriptase is a catalytic subunit of the enzyme telomerase, which, together with the telomerase RNA component (TERC), comprises the most important unit of the telomerase complex.

<span class="mw-page-title-main">Telomerase RNA component</span> NcRNA found in eukaryotes

Telomerase RNA component, also known as TR, TER or TERC, is an ncRNA found in eukaryotes that is a component of telomerase, the enzyme used to extend telomeres. TERC serves as a template for telomere replication by telomerase. Telomerase RNAs differ greatly in sequence and structure between vertebrates, ciliates and yeasts, but they share a 5' pseudoknot structure close to the template sequence. The vertebrate telomerase RNAs have a 3' H/ACA snoRNA-like domain.

<span class="mw-page-title-main">ACD (gene)</span> Protein-coding gene in the species Homo sapiens

Adrenocortical dysplasia protein homolog is a protein that in humans is encoded by the ACD gene.

<span class="mw-page-title-main">TEP1</span> Protein-coding gene in the species Homo sapiens

Telomerase protein component 1 is an enzyme that in humans is encoded by the TEP1 gene.

<span class="mw-page-title-main">PINX1</span> Protein-coding gene in the species Homo sapiens

PIN2/TERF1-interacting telomerase inhibitor 1, also known as PINX1, is a human gene. PINX1 is also known as PIN2 interacting protein 1. PINX1 is a telomerase inhibitor and a possible tumor suppressor.

<span class="mw-page-title-main">Sierra Sciences</span> US biotechnology company

Sierra Sciences, LLC is a biotechnology company founded by William H. Andrews, former director of molecular biology at Geron Corporation. Andrews founded Sierra Sciences in 1999 in Reno, Nevada, with the goal of preventing and/or reversing cellular senescence, and ultimately curing diseases associated with human aging, including the aging process itself.

<span class="mw-page-title-main">Cycloastragenol</span> Chemical compound

Cycloastragenol is a triterpenoid isolated from various legume species in the genus Astragalus that is purported to have telomerase activation activity. A preliminary in vitro study on human CD4 and CD8 T cells found that cycloastragenol may moderately increase telomerase activity and inhibit the onset of cellular senescence.

<span class="mw-page-title-main">Titia de Lange</span> Dutch geneticist

Titia de Lange is the Director of the Anderson Center for Cancer Research, the Leon Hess professor and the head of Laboratory Cell Biology and Genetics at Rockefeller University.

<span class="mw-page-title-main">Telomeric repeat–containing RNA</span> Long non-coding RNA transcribed from telomeres

Telomeric repeat–containing RNA (TERRA) is a long non-coding RNA transcribed from telomeres - repetitive nucleotide regions found on the ends of chromosomes that function to protect DNA from deterioration or fusion with neighboring chromosomes. TERRA has been shown to be ubiquitously expressed in almost all cell types containing linear chromosomes - including humans, mice, and yeasts. While the exact function of TERRA is still an active area of research, it is generally believed to play a role in regulating telomerase activity as well as maintaining the heterochromatic state at the ends of chromosomes. TERRA interaction with other associated telomeric proteins has also been shown to help regulate telomere integrity in a length-dependent manner.

Bryant Villeponteau is an American scientist, entrepreneur, and longevity expert who has worked in both academia and industry.

<span class="mw-page-title-main">BioViva</span> American biotechnology company

BioViva is an American biotechnology gene therapy company, based in Bainbridge Island, Washington, researching treatments to interfere in the aging process in humans.

Peter Michael Lansdorp is recognized for his contributions in the fields of hematology, medical genetics and cancer research. He has made significant contributions to the understanding of genome instability, particularly in relation to aging and cancer. His research has focused on the biology of blood-forming stem cells, telomeres and genome analysis. He is also known for developing techniques including single cell Strand-seq and fluorescence in situ hybridization (FISH) techniques such as Q-FISH and flow FISH.

References

  1. 1 2 3 4 5 6 Andrews, B. (2011), "Personal Profile: Interview with Bill Andrews, Ph.D.", Rejuvenation Research , 14 (4): 457–461, doi:10.1089/rej.2011.1237, PMID   21851179
  2. 1 2 3 4 5 The Man Who Would Stop Time, Popular Science, 2011
  3. ↑ Mammalian telomerase, United States Patent, 1996
  4. ↑ Feng, J; Funk, WD; Wang, SS; et al. (1995), "The RNA component of human telomerase.", Science , 269 (5228): 1236–41, doi:10.1126/science.7544491, PMID   7544491, S2CID   9440710
  5. 1 2 Telomerase, United States Patent, 2001
  6. ↑ Zvereva, M. I.; Shcherbakova, D. M.; Dontsova, O. A. (2010). "Telomerase: structure, functions, and activity regulation". Biochemistry. Biokhimiia. 75 (13): 1563–1583. doi:10.1134/s0006297910130055. ISSN   1608-3040. PMID   21417995. S2CID   15987343.
  7. ↑ "An Interview with Bill Andrews, Ph.D." ACIM Connect. Retrieved July 14, 2021.
  8. ↑ Dr. William H. Andrews
  9. ↑ Peters, Michael A. (May 12, 2021). "Against death. Longevity forever!". Educational Philosophy and Theory. 53 (6): 559–562. doi: 10.1080/00131857.2019.1684803 . ISSN   0013-1857.
  10. ↑ Past Winners, Intellectual Property Organization, 2005
  11. ↑ Harley, CB; Liu, W; Blasco, M; et al. (2011), "A Natural Product Telomerase Activator As Part of a Health Maintenance Program", Rejuvenation Research , 14 (1): 45–56, doi:10.1089/rej.2010.1085, PMC   3045570 , PMID   20822369
  12. 1 2 Sierra Sciences: Achievements and Intellectual Property., Sierra Sciences, 2011
  13. ↑ The Vision, Stayoung.info, 2011
  14. ↑ "Telomerase Therapies?". Josh Mitteldorf. November 1, 2012. Retrieved July 14, 2021.
  15. ↑ "The Science – Libella Gene Therapeutics" . Retrieved July 14, 2021.
  16. ↑ admin. "Bill Andrews, Ph.D." defytime®. Retrieved July 14, 2021.
  17. ↑ Badwater 2008 results, Ultra Signup, 2008
  18. ↑ 2009 Badwater Ultramarathon Results, AdventureCORPS, 2009
  19. ↑ "Reading Length | Search engine for books". www.readinglength.com. Retrieved July 14, 2021.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.